New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
08:46 EDTSRNESorrento Therapeutics receives two NIH small business grants
Sorrento Therapeutics announced that it has received two NIH small business grants which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. Sorrento's highly diverse, fully human G-MAB library and proprietary antibody conjugation technology platforms have broad applications beyond oncology, including other therapeutic areas such as anti-infectives and auto-immune diseases.
News For SRNE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
07:59 EDTSRNESorrento Therapeutics price target raised to $26 from $17 at Brean Capital
Brean Capital raised its price target on Sorrento Therapeutics (SRNE) to $26 from $17 as they believe the successful Nantkwest (NK) IPO has validated the company and its strategy. The firm noted Sorrento is an equal partner in the ownership of Nantkwest and thus feels it deserves a similar valuation, which is not priced in. Brean Capital reiterated its Buy rating on Sorrento shares.
July 23, 2015
10:05 EDTSRNEHigh option volume stocks
Subscribe for More Information
July 17, 2015
18:01 EDTSRNESorrento Therapeutics Chief Commercial Officer George Uy to leave company
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use